Abstract
# Hot Take: The FDA Just Quietly Moved 5 Peptides — And It's Not What Most Clinics Are Telling You ## What happened on April 15 The FDA's Pharmacy Compounding Advisory Committee (PCAC) removed five peptides — **BPC-157, GHK-Cu, CJC-1295, semaglutide, and tirzepatide** — from the 503A Category 2 bulks list. That's the list of substances with safety or efficacy questions that compounding pharmacies can't use. Effective date: **April 22, 2026**. Within 24 hours, half the peptide influencer world declared "peptides are legal again." That framing is wrong, and running with it is how clinics end up on an FDA warning letter. Here's what actually happened — and why it still matters. --- ## What this decision is — and isn't **What it is:** A procedural removal. The nominators who originally asked the FDA to evaluate these peptides for Category 1 (cleared for compounding) withdrew their nominations. The FDA then removed the peptides from Category 2 because there's no active petition to review. **What it isn't:** An affirmative ruling that these compounds are safe, effective, or cleared for compounding. The FDA did not vote "yes" on any of them. They were removed because no one is asking the question anymore — not because the FDA answered it. **What that means in practice:** Between April 22 and the next PCAC meeting on **July 23–24, 2026**, compounding pharmacies sit in a regulatory gray zone. Technically not on the restricted list. Still not formally cleared. The FDA can issue guidance, warning letters, or enforcement actions at any point in that window. Treating it as a green light is a misread of how the FDA actually moves. --- ## Why this matters for patients If you're on peptide therapy through a compounding pharmacy, three things change for you over the next 90 days: **1. Access may temporarily improve.** Pharmacies that paused production during the Category 2 period can now source bulk API. Expect shorter wait times and possibly stabilized pricing on BPC-1…
All information is presented for Research Use Only (RUO). Not medical advice.